Zafar Iqbal

21st wieku innowacje w najnowszych technologiach doprowadzily do odkrycia nowych genetycznych, immunologicznych i kom rkowych mechanizm w biologicznych leżących u podstaw biologii i partenogenezy r żnych chor b, w tym nowotwor w. Dzięki temu nastąpila szczeg lna rewolucja w diagnostyce, prognozowaniu i leczeniu hematologicznych nowotwor w zlośliwych, w szczeg lności bialaczek i chloniak w. Wiele biomarker w molekularnych i immunologicznych zostalo odkrytych i wykorzystanych jako cele lek w w celu opracowania ukierunkowanych terapii molekularnych w tym zakresie. Wysilki te szczeg lnie zrewolucjonizowaly kliniczne leczenie przewleklej bialaczki szpikowej, kt ra w pierwszym kwartale XXI wieku przeksztalcila się z choroby śmiertelnej w "prawie wyleczony" rak. Niemniej jednak, ze względu na diabelską, dynamiczną naturę raka jako choroby, nadal istnieje wiele wyzwań w prognozowaniu i leczeniu CML. Niniejsza książka zawiera opis patogenezy molekularnej, jak r wnież obecnych i przyszlych terapii celowych w CML. Podkreśla r wnież kilka brakujących lekcji i wyzwań w diagnostyce, stratyfikacji prognostycznej, monitorowania leczenia, oporności na leki i remisji bez leczenia CML, jak r wnież gl wnych obszar w zainteresowania w leczeniu CML i badań.

Les innovations du 21e si cle dans les technologies de pointe ont conduit la d couverte de nouveaux m canismes g n tiques, immunologiques et biologiques cellulaires qui sous-tendent la biologie et la parth nogen se de diff rentes maladies, dont le cancer. Une r volution particuli re a ainsi t r alis e dans le diagnostic, le pronostic et le traitement des h mopathies malignes, en particulier des leuc mies et des lymphomes. De nombreux biomarqueurs mol culaires et immunologiques ont t d couverts et utilis s comme cibles m dicamenteuses pour d velopper des th rapies mol culaires cibl es cet gard. Ces efforts ont sp cifiquement r volutionn la gestion clinique de la leuc mie my lo de chronique, qui est pass e d'une maladie mortelle un cancer "presque gu ri" au cours du premier quart du 21e si cle. N anmoins, en raison de la nature diablement dynamique du cancer en tant que maladie, le pronostic et le traitement de la LMC pr sentent encore de nombreux d fis. Ce livre fournit un compte rendu de la pathogen se mol culaire ainsi que des th rapies cibl es actuelles et futures dans la LMC. Il met galement en vidence certaines le ons et certains d fis manquants en mati re de diagnostic, de stratification du pronostic, de surveillance du traitement, de r sistance aux m dicaments et de r mission sans traitement de la LMC, ainsi que les principaux domaines d'int r t en mati re de traitement et de recherche sur la LMC.

Le innovazioni del 21 secolo nelle tecnologie all'avanguardia hanno portato alla scoperta di nuovi meccanismi genetici, immunologici e biologici cellulari alla base della biologia e della partenogenesi di diverse malattie, tra cui il cancro. Una rivoluzione speciale stata fatta da questa scoperta nella diagnosi, nella prognosi e nel trattamento dei tumori maligni ematologici, in particolare le leucemie e i linfomi. Molti biomarcatori molecolari e immunologici sono stati scoperti e utilizzati come bersagli farmacologici per sviluppare terapie molecolari mirate a questo proposito. Questi sforzi hanno rivoluzionato in modo specifico la gestione clinica della leucemia mieloide cronica che stata trasformata da malattia mortale a cancro "quasi guarito" nel primo quarto del 21 secolo. Tuttavia, a causa della natura diabolica e dinamica del cancro come malattia, ci sono ancora molte sfide nella prognosi e nel trattamento della LMC. Questo libro fornisce un resoconto della patogenesi molecolare e delle attuali e future terapie mirate nella CML. Evidenzia anche alcune lezioni mancanti e sfide nella diagnosi, nella stratificazione prognostica, nel monitoraggio del trattamento, nella resistenza ai farmaci e nella remissione senza trattamento della CML, cos come le principali aree di interesse nel trattamento e nella ricerca della CML.

As inova es do s culo XXI nas tecnologias de ponta levaram descoberta de novos mecanismos gen ticos, imunol gicos e biol gicos celulares subjacentes biologia e partenog nese de diferentes doen as, incluindo o cancro. Uma revolu o especial foi feita por isto no diagn stico, progn stico e tratamento de malignidades hematol gicas especificamente leucemias e linfomas. Muitos biomarcadores moleculares e imunol gicos foram descobertos e utilizados como alvos de medicamentos para desenvolver terapias moleculares espec ficas neste sentido. Estes esfor os t m revolucionado especificamente o tratamento cl nico da Leucemia Miel ide Cr nica, que se transformou de uma doen a fatal em um c ncer "quase curado" no primeiro quarto do s culo 21. No entanto, devido natureza din mica do diabo do c ncer como doen a, ainda existem muitos desafios no progn stico e tratamento da LMC. Este livro fornece um relato da patog nese molecular, bem como terapias direcionadas atuais e prospectivas na LMC. Ele tamb m destaca algumas li es e desafios faltantes no diagn stico, estratifica o progn stica, monitoramento do tratamento, resist ncia aos medicamentos e remiss o livre de tratamento de CML, bem como as principais reas de foco no tratamento e pesquisa de CML.

21. Jahrhundert haben Innovationen in den Spitzentechnologien zur Entdeckung neuartiger genetischer, immunologischer und zellbiologischer Mechanismen gef hrt, die der Biologie und Parthenogenese verschiedener Krankheiten einschlie lich Krebs zugrunde liegen. Dadurch wurde eine besondere Revolution in der Diagnose, Prognose und Behandlung h matologischer Malignome, insbesondere von Leuk mien und Lymphomen, ausgel st. Viele molekulare und immunologische Biomarker wurden entdeckt und als Angriffspunkte f r Medikamente genutzt, um in dieser Hinsicht zielgerichtete molekulare Therapien zu entwickeln. Diese Bem hungen haben insbesondere die klinische Behandlung der chronischen myeloischen Leuk mie revolutioniert, die sich im ersten Viertel des 21. Jahrhunderts von einer t dlichen Krankheit zu einem "fast geheilten" Krebs entwickelt hat. Dennoch gibt es aufgrund der teuflisch dynamischen Natur der Krebserkrankung immer noch viele Herausforderungen bei der Prognose und Behandlung der CML. Dieses Buch gibt einen berblick ber die molekulare Pathogenese sowie ber aktuelle und zuk nftige zielgerichtete Therapien bei CML. Es hebt auch einige fehlende Lektionen und Herausforderungen bei der Diagnose, der prognostischen Stratifizierung, der Therapie berwachung, der Arzneimittelresistenz und der behandlungsfreien Remission der CML sowie die wichtigsten Schwerpunktbereiche in der CML-Behandlung und -Forschung hervor.

Latest innovations in molecular biology, genetics and cell biology have revolutionized the understanding of disease parthenogenesis and efforts related to discovery of novel disease biomarkers and drug targets, eventually leading to development of more effective medication with fewer side effects. A special focus of these cutting-edge approaches has been the field of leukemia and other blood cancers with discovery of many new cancer-causing genes and therapies directly targeting cancer cells and oncogenes. Acute Myeloid Leukemia (AML) has undergone major innovations in terms of early diagnosis, molecular sub-classification of the disease, prognostic stratification and new drug discovery, culminating into patient-tailored treatment of AML patients. This books provides an account of the biology and account of genetic basis of AML and their implication in clinic and research.

21st century innovations in cutting-edge technologies have led to discovery of novel genetic, immunology and cell biological mechanisms underlying biology and parthenogenesis of diseases. A special revolution has been made by this in diagnosis, prognosis and treatment of hematological malignancies specifically leukemia. A large number of molecular genetic assays have been developed that help in selection of appropriate drugs and clinical protocols for leukemia patients, leading to patient-tailored treatment with higher clinical outcomes and fewer drug side-effects. In this era of genomic medicine, basic genetic testing had become need of every clinic and hospital. This book provides an account of classical and novel genetic abnormalities in different types of leukemia and their clinical implication. It provides standard clinically validated protocols for detection of classical genetic aberrations in leukemia. It also provides an up-to-date account of mutations associated with different types of hematological malignancies.

Axoplasmic transport is the intracellular movement of cellular components required for the maintenance and normal physiological functioning of neuronal cells. This book provides an up to date reference for both established investigators as well as for those entering in the field. This volume describes the history and methods of the study of transport and the involvement of energy, ions, calmodulin, microtubules and other cellular components in transport. It also discusses the transport of polypeptides, lipids, nucleic acids, neutrotransmitter containing components and various other particles in nerve fibres. A significant portion of this book is devoted to axoplasmic transport, regeneration and the relevance of transport in neurotropic functions are described in the alst four chapters, followed by a discussion on the mechanism of axoplasmic transport.